rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2018-671-674rsp-2634Research ArticleДИСКУССИИDISCUSSIONДискуссионные проблемы потенциального вреда применения ингибиторов протонного насосаPOTENTIAL HARMS OF THE USE OF PROTON PUMP INHIBITORS: DEBATABLE PROBLEMSМуравьевЮ. В.MuravyevYu. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

murawyu@mail.ruБобковаО. Р.BobkovaO. R.

115522, Москва, Каширское шоссе, 34А

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201809112018565671674Copyright © Муравьев Ю.В., Бобкова О.Р., 20182018Муравьев Ю.В., Бобкова О.Р.Muravyev Y.V., Bobkova O.R.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2634

В статье обсуждаются данные о высокой частоте назначения ингибиторов протонного насоса без показаний и о проявлениях потенциального вреда их применения.

The paper discusses data on the high frequency of non-indicated use of proton pump inhibitors and on the manifestations of potential harms of their use.

ингибиторы протонного насосавредревматоидный артритгиперчувствительные реакцииproton pump inhibitorsharmrheumatoid arthritishypersensitivity reactionsReferencesФедеральное руководство по использованию лекарственных средств (формулярная система). Выпуск XV. Москва: Эхо; 2014. 1020 с. [Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) [Federal Guidelines for the Use of Medicines (Formulary System)]. Vol. XV. Moscow: Ekho;2014. 1020 p. (In Russ.)].Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск XV. Москва: Эхо; 2014. 1020 с. [Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) [Federal Guidelines for the Use of Medicines (Formulary System)]. Vol. XV. Moscow: Ekho;2014. 1020 p. (In Russ.)].Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med. 2011;78(1):39-49. doi: 10.3949/ccjm.77a.10087Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med. 2011;78(1):39-49. doi: 10.3949/ccjm.77a.10087Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747-8. doi: 10.1001/archinternmed.2010.64Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747-8. doi: 10.1001/archinternmed.2010.64U.S. Food and Drug Administration (FDA). FDA Drug Safety Podcast for Healthcare Professionals:Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm245455.htm, 2009.U.S. Food and Drug Administration (FDA). FDA Drug Safety Podcast for Healthcare Professionals:Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm245455.htm, 2009.Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25:333-40. doi: 10.1046/j.1365-2710.2000.00312.xNaunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25:333-40. doi: 10.1046/j.1365-2710.2000.00312.xMat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31-4. doi: 10.1111/j.1742-1241.2004.00298.xMat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31-4. doi: 10.1111/j.1742-1241.2004.00298.xWalker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci. 2001;23:116-7.doi: 10.1023/A:1011278030001Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci. 2001;23:116-7.doi: 10.1023/A:1011278030001Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28:189-93. doi: 10.1007/s11096-006-9028-4Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28:189-93. doi: 10.1007/s11096-006-9028-4Pham CQD, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40:1261-6. doi: 10.1345/aph.1G703Pham CQD, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40:1261-6. doi: 10.1345/aph.1G703Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2-3. doi: 10.1136/bmj.39406.449456.BEForgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2-3. doi: 10.1136/bmj.39406.449456.BEChoudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445-8. doi: 10.1093/qjmed/hcn035Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445-8. doi: 10.1093/qjmed/hcn035Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203-9. doi: 10.1111/j.1365-2036.2005.02454.xZink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203-9. doi: 10.1111/j.1365-2036.2005.02454.xStrid H, Simren M, Bjornsson ES. Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association. Nephrol Dial Transplant. 2003;18:570-5. doi: 10.1093/ndt/18.3.570Strid H, Simren M, Bjornsson ES. Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association. Nephrol Dial Transplant. 2003;18:570-5. doi: 10.1093/ndt/18.3.570Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867-78. doi: 10.1001/jama.2008.892Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867-78. doi: 10.1001/jama.2008.892Grady D, Redberg RF. Less is more: how less health care can result in better health. Arch Intern Med. 2010;170:749-50. doi: 10.1001/archinternmed.2010.90Grady D, Redberg RF. Less is more: how less health care can result in better health. Arch Intern Med. 2010;170:749-50. doi: 10.1001/archinternmed.2010.90Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834-6. doi: 10.1056/NEJMc066308Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834-6. doi: 10.1056/NEJMc066308Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237-41. doi: 10.3109/0886022X.2015.1057800Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237-41. doi: 10.3109/0886022X.2015.1057800Semb S, Helgstrand F, Hjorne F, Bytzer P Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication. World J Gastroenterol. 2017;23(37):6907-10. doi: 10.3748/wjg.v23.i37.6907Semb S, Helgstrand F, Hjorne F, Bytzer P Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication. World J Gastroenterol. 2017;23(37):6907-10. doi: 10.3748/wjg.v23.i37.6907Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-42. doi: 10.1001/jama.2013.280490Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-42. doi: 10.1001/jama.2013.280490Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-90. doi: 10.1016/j.cgh.2012.12.011Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-90. doi: 10.1016/j.cgh.2012.12.011Wang L, Li M, Cao Y, at al. Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. Sci Rep. 2017;7(1):5527. doi: 10.1038/s41598-017-05552-1Wang L, Li M, Cao Y, at al. Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. Sci Rep. 2017;7(1):5527. doi: 10.1038/s41598-017-05552-1Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339-47. doi: 10.1007/s00198-015-3365-xZhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339-47. doi: 10.1007/s00198-015-3365-xO'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-81. doi: 10.1016/j.amjmed.2005.02.007O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-81. doi: 10.1016/j.amjmed.2005.02.007Targownik LE, Leslie WD, Davison KS, et al; CaMos Research Group. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361-9. doi: 10.1038/ajg.2012.200Targownik LE, Leslie WD, Davison KS, et al; CaMos Research Group. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361-9. doi: 10.1038/ajg.2012.200Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95-101. doi: 10.1038/ajg.2016.481Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95-101. doi: 10.1038/ajg.2016.481Freedberg DE, Kim LS, Yang YX. The risks and benefits of longterm use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-15. doi: 10.1053/j.gastro.2017.01.031Freedberg DE, Kim LS, Yang YX. The risks and benefits of longterm use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-15. doi: 10.1053/j.gastro.2017.01.031Kwok CS, Arthur AK, Anibueze CI, at al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: metaanalysis. Am J Gastroenterol. 2012;107(7):1011-9. doi: 10.1038/ajg.2012.108Kwok CS, Arthur AK, Anibueze CI, at al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: metaanalysis. Am J Gastroenterol. 2012;107(7):1011-9. doi: 10.1038/ajg.2012.108Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883-885.e9. doi: 10.1053/j.gastro.2015.06.043Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883-885.e9. doi: 10.1053/j.gastro.2015.06.043Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001-10. doi: 10.1038/ajg.2012.179Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001-10. doi: 10.1038/ajg.2012.179Tariq R, Singh S, Gupta A, at al. Association of gastric acid suppression with recurrent Clostridium difficile infection:a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784-91. doi: 10.1001/jamainternmed.2017.0212Tariq R, Singh S, Gupta A, at al. Association of gastric acid suppression with recurrent Clostridium difficile infection:a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784-91. doi: 10.1001/jamainternmed.2017.0212Khanna S, Aronson SL, Kammer PP, еt al. Gastric acid suppression and outcomes in Clostridium difficile infection: a populationbased study. Mayo Clin Proc. 2012;87(7):636-42. doi: 10.1016/j.mayocp.2011.12.021Khanna S, Aronson SL, Kammer PP, еt al. Gastric acid suppression and outcomes in Clostridium difficile infection: a populationbased study. Mayo Clin Proc. 2012;87(7):636-42. doi: 10.1016/j.mayocp.2011.12.021Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153-63. doi: 10.1681/ASN.2015121377Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153-63. doi: 10.1681/ASN.2015121377Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a populationbased cohort study. CMAJ Open. 2015;3(2):E166-E171. doi: 10.9778/cmajo.20140074Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a populationbased cohort study. CMAJ Open. 2015;3(2):E166-E171. doi: 10.9778/cmajo.20140074Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702-10. doi: 10.1053/j.gastro.2017.05.046Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702-10. doi: 10.1053/j.gastro.2017.05.046International Society of Nephrology. Summary of recommendation statements. Kidney Int Suppl. 2013;3(1):5-14. doi: 10.1038/kisup.2012.77International Society of Nephrology. Summary of recommendation statements. Kidney Int Suppl. 2013;3(1):5-14. doi: 10.1038/kisup.2012.77Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419-28. doi: 10.1007/s00406-014-0554-0Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419-28. doi: 10.1007/s00406-014-0554-0Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410-6. doi: 10.1001/jamaneurol.2015.4791Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410-6. doi: 10.1001/jamaneurol.2015.4791Taipale H, Tolppanen AM, Tiihonen M, et al. No association between proton pump inhibitor use and risk of Alzheimer's disease [pub. online ahead of print July 11, 2017]. Am J Gastroenterol. doi: 10.1038/ajg.2017.196Taipale H, Tolppanen AM, Tiihonen M, et al. No association between proton pump inhibitor use and risk of Alzheimer's disease [pub. online ahead of print July 11, 2017]. Am J Gastroenterol. doi: 10.1038/ajg.2017.196Badiola N, Alcalde V, Pujol A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837. doi: 10.1371/journal.pone.0058837Badiola N, Alcalde V, Pujol A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837. doi: 10.1371/journal.pone.0058837Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955-60. doi: 10.1001/jama.292.16.1955Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955-60. doi: 10.1001/jama.292.16.1955Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-9. doi: 10.1503/cmaj.092129Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-9. doi: 10.1503/cmaj.092129Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735. doi: 10.1136/bmjopen-2016-015735Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735. doi: 10.1136/bmjopen-2016-015735Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. doi: 10.1016/S0140-6736(96)09457-3Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. doi: 10.1016/S0140-6736(96)09457-3Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associatedwith concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44. doi: 10.1001/jama.2009.261Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associatedwith concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44. doi: 10.1001/jama.2009.261Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.Circulation. 2011;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640Circulation. 2011;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378-86. doi: 10.7326/0003-4819-153-6-201009210-00005Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378-86. doi: 10.7326/0003-4819-153-6-201009210-00005Douglas IJ, Evans SJ, Hingorani AD, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. 2012;345:e4388. doi: 10.1136/bmj.e4388Douglas IJ, Evans SJ, Hingorani AD, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. 2012;345:e4388. doi: 10.1136/bmj.e4388O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-97. doi: 10.1016/S0140-6736(09)61525-7O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-97. doi: 10.1016/S0140-6736(09)61525-7Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. doi: 10.1056/NEJMoa1007964Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. doi: 10.1056/NEJMoa1007964Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321-41. doi: 10.1016/j.jacc.2010.05.013Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321-41. doi: 10.1016/j.jacc.2010.05.013Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690. doi: 10.1136/bmj.d2690Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690. doi: 10.1136/bmj.d2690Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015;10(6):e0124653.doi: 10.1371/journal.pone.0124653Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015;10(6):e0124653.doi: 10.1371/journal.pone.0124653Otani IM, Banerji A. Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management. Curr Allergy Asthma Rep. 2016;16(3):17. doi: 10.1007/s11882-016-0595-8Otani IM, Banerji A. Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management. Curr Allergy Asthma Rep. 2016;16(3):17. doi: 10.1007/s11882-016-0595-8Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221-9. doi: 10.1111/all.13235Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221-9. doi: 10.1111/all.13235Correia O, Viana H, Azevedo R, et al. Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration. Clin Exp Dermatol. 2001;26:455-6. doi: 10.1046/j.1365-2230.2001.00857.xCorreia O, Viana H, Azevedo R, et al. Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration. Clin Exp Dermatol. 2001;26:455-6. doi: 10.1046/j.1365-2230.2001.00857.xDam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol. 2008;88:87-9. doi: 10.2340/00015555-0335Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol. 2008;88:87-9. doi: 10.2340/00015555-0335Bracke A, Nijsten T, Vandermaesen J, et al. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol. 2005;1:1. doi: 10.1080/00015550510026668Bracke A, Nijsten T, Vandermaesen J, et al. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol. 2005;1:1. doi: 10.1080/00015550510026668Panting K, Pinto M, Ellison J. Lansoprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 2009;34:733-4. doi: 10.1111/j.1365-2230.2008.03105.xPanting K, Pinto M, Ellison J. Lansoprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 2009;34:733-4. doi: 10.1111/j.1365-2230.2008.03105.xMankia SK, Rytina E, Burrows NP. Omeprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol Wiley. 2010;35:e1-2. doi: 10.1111/j.1365-2230.2008.03125.xMankia SK, Rytina E, Burrows NP. Omeprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol Wiley. 2010;35:e1-2. doi: 10.1111/j.1365-2230.2008.03125.xToms-Whittle L, John L, Buckley D. Drug-induced subacute cutaneous lupus erythematosus associated with omeprazole. Clin Exp Dermatol. 2011;36:281-3. doi: 10.1111/j.1365-2230.2010.03926.xToms-Whittle L, John L, Buckley D. Drug-induced subacute cutaneous lupus erythematosus associated with omeprazole. Clin Exp Dermatol. 2011;36:281-3. doi: 10.1111/j.1365-2230.2010.03926.xWee J, Natkunarajah J, Marsden R. A difficult diagnosis: druginduced subacute cutaneous lupus erythematosus (SCLE) triggered by omeprazole in a patient with pre-existing idiopathic SCLE. Clin Exp Dermatol. 2012;37:445-6. doi: 10.1111/j.1365-2230.2011.04245.xWee J, Natkunarajah J, Marsden R. A difficult diagnosis: druginduced subacute cutaneous lupus erythematosus (SCLE) triggered by omeprazole in a patient with pre-existing idiopathic SCLE. Clin Exp Dermatol. 2012;37:445-6. doi: 10.1111/j.1365-2230.2011.04245.xMcCourt C, Somerville J, McKenna K. Anti-Ro and anti-La antibody positive subacute cutaneous lupus erythematosus (SCLE) induced by lansoprazole. Eur J Dermatol. 2010;20:860-1.McCourt C, Somerville J, McKenna K. Anti-Ro and anti-La antibody positive subacute cutaneous lupus erythematosus (SCLE) induced by lansoprazole. Eur J Dermatol. 2010;20:860-1.Almebayadh M, Regnier-Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. Dermatology. 2013;226:119-23. doi: 10.1159/000346694Almebayadh M, Regnier-Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. Dermatology. 2013;226:119-23. doi: 10.1159/000346694Alcantara-Gonzalez J, Truchuelo-DТez MT, Gonzalez-Garcia C, Jaen Olasolo P. [Esomeprazole-induced subacute cutaneous lupus erythematosus]. Actas Dermosifil. 2011;102:638-40. doi: 10.1016/j.ad.2010.09.018Alcantara-Gonzalez J, Truchuelo-DТez MT, Gonzalez-Garcia C, Jaen Olasolo P. [Esomeprazole-induced subacute cutaneous lupus erythematosus]. Actas Dermosifil. 2011;102:638-40. doi: 10.1016/j.ad.2010.09.018

The authors declare that there are no conflicts of interest present.